Target intelligence / Profile preview

16S ribosomal RNA A-site (16S rRNA A-site) (16S rRNA A-site)

Target
16S rRNA A-site
Molecular classification
Ribosomal RNA, Nucleic acid, Ribosome component
01

Overview

The 16S ribosomal RNA (rRNA) A-site is a highly conserved and functionally essential region within the 30S small subunit of the bacterial ribosome (Nature, 1987). It serves as the decoding center where the ribosome monitors the fidelity of codon-anticodon pairing between messenger RNA (mRNA) and aminoacyl-transfer RNA (tRNA) (Wikipedia, 2024). During translation, key adenine residues (A1492 and A1493) undergo conformational changes to stabilize correct tRNA binding (NIH, 2024). This site is a major therapeutic target for several classes of antibiotics, including aminoglycosides and tetracyclines (StatPearls, 2023). Aminoglycosides bind to the A-site and lock these adenine residues in an active conformation, which promotes the incorporation of incorrect amino acids and leads to bacterial cell death (NIH, 2024). Tetracyclines act by sterically hindering the binding of aminoacyl-tRNA to the A-site, effectively stopping protein elongation (NIH, 2016). Resistance is frequently mediated by 16S rRNA methyltransferases or specific point mutations that reduce drug affinity (NIH, 2024).

Other names
Decoding centerDecoding siteAminoacyl site30S A-site16S rRNA decoding region
02

Mechanism of action

Antibiotics targeting the 16S rRNA A-site typically inhibit protein synthesis by either sterically blocking the entry of aminoacyl-tRNA (e.g., tetracyclines) or by binding to the decoding center to induce conformational changes that cause mRNA misreading and mistranslation (e.g., aminoglycosides) (Nature, 1987; NIH, 2024).

03

Biological functions

Protein synthesisTranslationDecodingRibosome assembly
04

Disease associations

Infection
05

Safety considerations

OtotoxicityNephrotoxicityNeuromuscular blockadeMitochondrial toxicity due to structural similarity with human mitochondrial 12S rRNA (StatPearls, 2023; NIH, 2024)
06

Interacting drugs

Gentamicin

13 more in the full profile.

07

Biomarkers

16S rRNA methyltransferases (ArmA, RmtA, RmtB, NpmA)16S rRNA gene mutations (e.g., A1408G, G1405) (NIH, 2024)

Beyond the preview

Go deeper on 16S ribosomal RNA A-site (16S rRNA A-site) (16S rRNA A-site).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 16S ribosomal RNA A-site (16S rRNA A-site) (16S rRNA A-site).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call